- We continue to believe that speculation that Roche (OTC:RHHBY) is back evaluating Illumina (NASDAQ:ILMN) as a take-out, is real, which you can read about in … Continue Reading
Read nowResearch - Amedisys, Inc. (NASDAQ:AMED) took a 9% hit Monday, as the company announced a major restructuring of its home health services agreement with Humana (NYSE:HUM). HUM … Continue Reading
Read nowLong Ideas - For most mutual funds, tax-loss selling must be done by the end of Monday. As a result, pressure could come off names that have had … Continue Reading
Read nowLong Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR), to no one’s surprise, remains volatile. Notably, the stock hit an intraday low of $17.60 on October 5th, and closed Thursday 19.5% … Continue Reading
Read nowLong Ideas - Keryx Biopharmaceuticals (NASDAQ:KERX) announced disappointing news earlier this year for its cancer compound perifosine, and the stock remains in the penalty box. However, the story … Continue Reading
Read nowLong Ideas - In an 8K released on Wednesday morning, Amarin Corp. (NASDAQ:AMRN) revealed that the FDA still has not made a decision regarding Vascepa’s New Chemical Entity … Continue Reading
Read nowLong Ideas - Notwithstanding the take-out chatter on Illumina (NASDAQ:ILMN), with the potential that Roche (OTC:RHHBY) may take another run at the company for $60 a share (read … Continue Reading
Read now